peplomycin and Breast-Neoplasms

A phase II study of peplomycin, an analogue of bleomycin, was carried out in 42 patients with advanced or recurrent breast cancer by a cooperative group consisting of 15 institutes throughout Japan, and the following results were obtained. Among the 42 patients, 38 were evaluable, in whom the overall response rate was 7.9% (3/38). For the various histologic types, the response rate was 33.3% (2/6) for papillotubular carcinoma and 9.1% (1/11) for medullary tubular carcinoma. The response rate was 33.3% (2/6) in patients without prior treatment and 3.1% (1/32) in those with prior treatment. Side effects of nausea, anorexia, malaise, alopecia and pyrexia occurred frequently, and a decrease in WBC and an increase in GOT were observed temporally. Pulmonary toxicity was observed in 7 patients.

Topics: Adult; Aged; Anorexia; Bleomycin; Breast Neoplasms; Carcinoma; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Peplomycin

Topics: Antibiotics, Antineoplastic; Bleomycin; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Peplomycin; Postoperative Period

The application of a heat pad in the hyperthermia treatment of malignant skin tumors was examined. The temperature on the skin surface, and at a depth of 1 mm and 2 mm became 42C, 41C and 40C respectively, and was maintained for 4 hours. Two patients were treated with the heat pad alone, four were treated in combination with radiotherapy and one patient each with Pepleomycin injection and Bleomycin ointment. Irrespective of the above methods used, the heat pad was effective.

Topics: Adult; Aged; Bleomycin; Breast Neoplasms; Combined Modality Therapy; Female; Hot Temperature; Humans; Lung Neoplasms; Male; Middle Aged; Ointments; Peplomycin; Picibanil; Skin Neoplasms; Skin Temperature

The anticancer effect of peplomycin (PEP) on advanced or recurrent breast cancer was investigated clinically and histopathologically. Stage III (n = 12), Stage IV (n = 2) and recurrent (n = 6) breast cancer patients were treated with PEP of which 10 mg were administered 3 times a week for 3 weeks either intravenously (n = 13) or intra-arterially (n = 7, via a catheter inserted into the subclavian artery). A decrease in tumor volume of more than 50% was obtained in 38.5% of the intravenously treated cases and in 28.6% the intra-arterially treated cases. Histologically, grades II b and III were observed in 66% of patients according to Oboshi's classification. These investigations suggest the effectiveness of PEP on breast cancer.

Topics: Adult; Aged; Bleomycin; Breast Neoplasms; Female; Humans; Injections, Intra-Arterial; Injections, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Peplomycin

In the search for bleomycin analogues with less pulmonary toxicity than bleomycin itself, peplomycin was selected for a phase I clinical trial, based on experimental animal data. Eighteen patients received peplomycin at three exploratory levels. Six patients were treated at a level of 5 mg/m2, 8 patients at 10 mg/m2 and 4 patients at 15 mg/m2 of peplomycin, each dosage being given twice weekly intravenously. Pulmonary function tests were performed prior to treatment and serially thereafter. Pulmonary toxicity was encountered when the administered total dose of peplomycin was in the range 190-350 mg in patients who had received either 10 or 15 mg/m2 twice weekly. Pulmonary toxicity was not observed when the dosage of peplomycin was restricted to 5 mg/m2 twice weekly. During the trial no haematological, hepatic or renal changes induced by the drug were observed. Skin changes, stomatitis and fever were observed with increasing frequency the higher the cumulative dose of peplomycin, and these effects were similar to those seen with bleomycin. Two of fifteen patients with cervical cancer obtained a partial response, lasting 1 and 2 months respectively. Although peplomycin is free from pulmonary toxicity at a dose of 5 mg/m2 twice weekly, the maximum tolerated cumulative dose has still to be defined.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Kidney Neoplasms; Lung Diseases; Middle Aged; Ovarian Neoplasms; Peplomycin; Respiratory Function Tests; Skin Diseases; Uterine Cervical Neoplasms

Twelve patients with recurrent breast cancer were treated with Peplomycin monotherapy. Peplomycin was given intermittently with a dose of 10 mg intramuscularly twice a week. As side effects of Peplomycin, fever elevation in 75% (9/12), malaise in 67%, nausea and vomiting in 42%, anorexia in 42%, pulmonary toxicity in 8%, and loss of hair in 8%, were observed. Out of 8 evaluable cases, CR was obtained in 1, PR in 1, NC in 3, and PD in 3 cases, respectively.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Peplomycin